Over $1M in admin, marketing and staff. 300k more than last quarter but they are watching costs right?
MD is going to continue to cash his check and has NO incentive to progress clinical trials as fast as possible.
here’s some more BS where he is posting timelines that are impossible to hold him to account on:
”The timing of the initiation of the nine-month toxicology study will be dependent on progress of ATL1102 in DMD in Europe and continued interactions on the regulatory path in the US with the FDA.” great, very clear
”Site evaluations had been completed with follow on site selection close to finalization” literally same sentence as investor presentation in May.
”The second study is planned for 3Q/4QCY22”. Is it really that hard to know if you’ll have suitable aged mice and get a fixed timeline. Last I checked time was linear?
And, NO MENTION OF COVID????
how much confidence does this really give?
ANP Price at posting:
7.8¢ Sentiment: None Disclosure: Held
